Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms

European Urology

Volumn 64, Issue 2, 2013, Pages 228-243

  Füllhase, Claudius ^a   Chapple, Christopher ^b   Cornu, Jean Nicolas ^c   De Nunzio, Cosimo ^d   Gratzke, Christian ^a   Kaplan, Steven A ^e   Marberger, Michael ^f   Montorsi, Francesco ^g   Novara, Giacomo ^h   Oelke, Matthias ⁱ   Porst, Hartmut ^j   Roehrborn, Claus ^k   Stief, Christian ^a   McVary, Kevin T ^l  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c HÔPITAL TENON   (France)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j Institute of Urology and Andrology at Segeberger Kliniken   (Germany)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

5 reductase inhibitors; Lower urinary tract symptoms; Muscarinic antagonists; Prostatic hyperplasia

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROPIVERINE; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

ADD ON THERAPY; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ARTICLE; COCHRANE LIBRARY; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; HYPOTENSION; IMPOTENCE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE; MEDLINE; META ANALYSIS (TOPIC); MONOTHERAPY; OUTCOME ASSESSMENT; PHYTOTHERAPY; POSTVOID RESIDUAL URINE VOLUME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SABAL; SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY; URINE RETENTION; XEROSTOMIA;

EID: 84879907848     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.01.018     Document Type: Review

References (73)

1. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society Urology 61 2003 37 49
2. K.M.C. Verhamme, J.P. Dieleman, G.S. Bleumink, J. van der Lei, M.C.J.M. Sturkenboom Triumph Pan European Expert Panel Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - the Triumph project Eur Urol 42 2002 323 328
3. P. Boyle, C. Robertson, and C. Mazzetta The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study BJU Int 92 2003 409 414
4. K.S. Coyne, C.C. Sexton, and C.L. Thompson The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study BJU Int 104 2009 352 360
5. D.E. Irwin, Z.S. Kopp, B. Agatep, I. Milsom, and P. Abrams Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction BJU Int 108 2011 1132 1138
6. D.E. Irwin, I. Milsom, and S. Hunskaar Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol 50 2006 1306 1315 discussion 1314-5
7. A. Roosen, C.R. Chapple, and R.R. Dmochowski A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature Eur Urol 56 2009 810 820
8. M. Oelke, A. Bachmann, and A. Descazeaud EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction Eur Urol 64 2013 118 140
9. K.T. McVary, C.G. Roehrborn, and A.L. Avins Update on AUA guideline on the management of benign prostatic hyperplasia J Urol 185 2011 1793 1803
10. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 62 2009 1006 1012
11. Howick J, Chalmers I, Glasziou P., OCEBM Levels of Evidence Working Group. 2011 levels of evidence system. Centre for Evidence Based Medicine Web site. http://www.cebm.net/index.aspx?o=5513. Accessed May 1, 2012.
12. J. Jones, and D. Hunter Consensus methods for medical and health services research BMJ 311 1995 376 380
13. H. Okada, N. Kawaida, T. Ogawa, S. Arakawa, O. Matsumoto, and S. Kamidono Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group Scand J Urol Nephrol 30 1996 379 385
14. H.C. Kuo Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia Urol Int 60 1998 85 91
15. H. Lepor, W.O. Williford, and M.J. Barry The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group N Engl J Med 335 1996 533 539
16. H. Lepor, W.O. Williford, M.J. Barry, C. Haakenson, and K. Jones The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group J Urol 160 1998 1358 1367
17. F.M.J. Debruyne, A. Jardin, and D. Colloi Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group Eur Urol 34 1998 169 175
18. T.M. Johnson II, K. Jones, W.O. Williford, M.H. Kutner, M.M. Issa, and H. Lepor Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial J Urol 170 2003 145 148
19. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
20. T.M. Johnson II, P.K. Burrows, and J.W. Kusek The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia J Urol 178 2007 2045 2050 discussion 2050-1
21. S.A. Kaplan, J.D. McConnell, and C.G. Roehrborn Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater J Urol 175 2006 217 220 discussion 220-1
22. R.S. Kirby, C. Roehrborn, and P. Boyle Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology 61 2003 119 126
23. C.G. Roehrborn, P. Siami, and J. Barkin The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study J Urol 179 2008 616 621 discussion 621
24. C.G. Roehrborn, P. Siami, and J. Barkin The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study Eur Urol 55 2009 461 471
25. J. Barkin, C.G. Roehrborn, and P. Siami Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial BJU Int 103 2009 919 926
26. B.H. Chung, C.G. Roehrborn, and P. Siami Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH Prostate Cancer Prostatic Dis 12 2009 152 159
27. E. Becher, C.G. Roehrborn, P. Siami, R.P. Gagnier, T.H. Wilson, and F. Montorsi The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study Prostate Cancer Prostatic Dis 12 2009 369 374
28. C.G. Roehrborn, P. Siami, and J. Barkin The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol 57 2010 123 131
29. F. Montorsi, T. Henkel, and A. Geboers Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study Int J Clin Pract 64 2010 1042 1051
30. F. Montorsi, C. Roehrborn, and J. Garcia-Penit The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study BJU Int 107 2011 1426 1431
31. C.G. Roehrborn, J. Barkin, and P. Siami Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial BJU Int 107 2011 946 954
32. J. Barkin, M. Guimarães, G. Jacobi, D. Pushkar, S. Taylor, and O.B. van Vierssen Trip α-Blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride Eur Urol 44 2003 461 466
33. R.C. Rosen, J.T. Wei, S.E. Althof, A.D. Seftel, M. Miner, and M.A. Perelman Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry Urology 73 2009 562 566
34. J.C. Nickel, J. Barkin, C. Koch, C. Dupont, and M. Elhilali Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers Can Urol Assoc J 2 2008 16 21
35. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
36. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
37. US Food and Drug Administration. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. US Food and Drug Administration Web site. http://www.fda.gov/ Drugs/DrugSafety/ucm258314.htm. Accessed May 1, 2012.
38. M. Marberger, S.J. Freedland, and G.L. Andriole Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study BJU Int 109 2012 1162 1169
39. I.M. Thompson, C. Chi, and D.P. Ankerst Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128 1133
40. H. Saito, T. Yamada, and H. Oshima A comparative study of the efficacy and safety of tamsulosin hydrochloride (Harnal capsules) alone and in combination with propiverine hydrochloride (BUP-4 tablets) in patients with prostatic hypertrophy associated with pollakiuria and/or urinary incontinence Jpn J Urol Surg 12 1999 525 536
41. K.S. Lee, M.S. Choo, and D.Y. Kim Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study J Urol 174 2005 1334 1338
42. S.A. Kaplan, C.G. Roehrborn, E.S. Rovner, M. Carlsson, T. Bavendam, and Z. Guan Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JAMA 296 2006 2319 2328
43. E.S. Rovner, K. Kreder, and D.O. Sussman Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms J Urol 180 2008 1034 1041
44. C.G. Roehrborn, S.A. Kaplan, S.R. Kraus, J.T. Wang, T. Bavendam, and Z. Guan Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB Urology 72 2008 1061 1067 discussion 1067
45. S.A. MacDiarmid, K.M. Peters, and A. Chen Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study Mayo Clin Proc 83 2008 1002 1010
46. S.A. Kaplan, C.G. Roehrborn, M. Chancellor, M. Carlsson, T. Bavendam, and Z. Guan Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score BJU Int 102 2008 1133 1139
47. C.G. Roehrborn, S.A. Kaplan, J.S. Jones, J.T. Wang, T. Bavendam, and Z. Guan Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size Eur Urol 55 2009 472 481
48. S.A. Kaplan, K. McCammon, R. Fincher, A. Fakhoury, and W. He Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency J Urol 182 2009 2825 2830
49. C. Chapple, S. Herschorn, P. Abrams, F. Sun, M. Brodsky, and Z. Guan Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers Eur Urol 56 2009 534 543
50. O. Yamaguchi, H. Kakizaki, and Y. Homma Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study Urology 78 2011 126 133
51. C.R. Chapple, S. Herschorn, P. Abrams, J.T. Wang, M. Brodsky, and Z. Guan Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration BJU Int 106 2010 1332 1338
52. M. Oelke, S. Murgas, I. Baumann, F. Schnabel, and M.C. Michel Efficacy of propiverine ER with or without alpha-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study World J Urol 29 2011 217 223
53. O. Nishizawa, O. Yamaguchi, M. Takeda, and O. Yokoyama Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics LUTS 3 2011 29 35
54. M. Gacci, G. Corona, and M. Salvi A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol 61 2012 994 1003
55. F. Giuliano, S.A. Kaplan, M.J. Cabanis, and B. Astruc Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects Urology 67 2006 1199 1204
56. S.M. Auerbach, M. Gittelman, A. Mazzu, F. Cihon, P. Sundaresan, and W.B. White Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia Urology 64 2004 998 1003 discussion 1003-4
57. R.A. Kloner, G. Jackson, and J.T. Emmick Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men J Urol 172 2004 1935 1940
58. C.F. Ng, A. Wong, C.W. Cheng, E.S. Chan, H.M. Wong, and S.M. Hou Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia J Urol 180 2008 1042 1046
59. T. Nieminen, T.L. Tammela, T. Koobi, and M. Kahonen The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement J Urol 176 2006 2551 2556
60. S.A. Kaplan, R.R. Gonzalez, and A.E. Te Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction Eur Urol 51 2007 1717 1723
61. G. Liguori, C. Trombetta, and G. De Giorgi Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report J Sex Med 6 2009 544 552
62. A. Bechara, S. Romano, and A. Casabe Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study J Sex Med 5 2008 2170 2178
63. Z. Jin, Z.C. Zhang, and J.H. Liu An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia Asian J Androl 13 2011 630 635
64. A. Tuncel, V. Nalcacioglu, K. Ener, Y. Aslan, O. Aydin, and A. Atan Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction World J Urol 28 2010 17 22
65. R. Rosen, J. Altwein, and P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 44 2003 637 649
66. P. Glemain, C. Coulange, T. Billebaud, B. Gattegno, R. Muszynski, and G. Loeb Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [in French] Prog Urol 12 2002 395 403 discussion 404
67. S. Bent, C. Kane, and K. Shinohara Saw palmetto for benign prostatic hyperplasia N Engl J Med 354 2006 557 566
68. F. Di Silverio, C. Bosman, and M. Salvatori Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) Eur Urol 47 2005 72 79 discussion 78-9
69. I. Ozdemir, O. Bozkurt, O. Demir, G. Aslan, and A.A. Esen Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms Urology 74 2009 431 435
70. H. Liu, P. Liu, and G. Mao Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial Urology 74 2009 130 136
71. D.E. Chung, A.E. Te, D.R. Staskin, and S.A. Kaplan Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams Urology 75 2010 1144 1148
72. B.G. Verheggen, R. Lee, and M.M. Lieuw On Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder J Med Econ 15 2012 586 600
73. T.E. Bjerklund Johansen, T.M. Baker, and L.K. Black Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial BJU Int 109 2012 731 738